Chronic renal allograft dysfunction
- PMID: 16120819
- DOI: 10.1681/ASN.2005050463
Chronic renal allograft dysfunction
Abstract
The major causes of renal transplant loss are death from vascular, malignant or infectious disease, and loss of the allograft from chronic renal dysfunction associated with the development of graft fibrosis and glomerulosclerosis. Chronic allograft nephropathy (CAN) is the histologic description of the fibrosis, vascular and glomerular damage occurring in renal allografts. Clinical programs rely on monitoring change in serum creatinine for identification of patients at risk of CAN, but this change occurs late in the course of the disease, and underestimates the severity of pathologic change. CAN has several causes: ischemia-reperfusion injury, ineffectively or untreated clinical and subclinical rejection, and superimposed calcineurin inhibitor nephrotoxicity, exacerbating pre-existing donor disease. Once established, interstitial fibrosis and arteriolar hyalinosis lead to progressive glomerulosclerosis over the subsequent years. There have been a number of approaches to treatment aimed at reducing the impact of CAN, mostly centered around avoidance of calcineurin inhibitors through their elimination in all, or just selected, patients. These immunosuppression strategies combine corticosteroids with azathioprine or mycophenolate mofetil, and/or sirolimus and everolimus. Late identification of CAN in individual patients has meant that strategies for intervening to prevent chronic renal allograft dysfunction and subsequent graft loss tend to be "too little and far too late."
Similar articles
-
The natural history of chronic allograft nephropathy.N Engl J Med. 2003 Dec 11;349(24):2326-33. doi: 10.1056/NEJMoa020009. N Engl J Med. 2003. PMID: 14668458
-
Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations.Kidney Int Suppl. 2005 Dec;(99):S108-12. doi: 10.1111/j.1523-1755.2005.09920.x. Kidney Int Suppl. 2005. PMID: 16336561
-
Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?Curr Opin Organ Transplant. 2008 Dec;13(6):614-21. doi: 10.1097/MOT.0b013e3283193bad. Curr Opin Organ Transplant. 2008. PMID: 19060552 Review.
-
Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.Pediatr Transplant. 2006 Jun;10(4):474-8. doi: 10.1111/j.1399-3046.2006.00503.x. Pediatr Transplant. 2006. PMID: 16712606
-
Chronic allograft nephropathy: current concepts and future directions.Transplantation. 2006 Mar 15;81(5):643-54. doi: 10.1097/01.tp.0000190423.82154.01. Transplantation. 2006. PMID: 16534463 Review.
Cited by
-
The immunomodulatory role of carbon monoxide during transplantation.Med Gas Res. 2013 Jan 7;3(1):1. doi: 10.1186/2045-9912-3-1. Med Gas Res. 2013. PMID: 23295066 Free PMC article.
-
Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.Br J Clin Pharmacol. 2016 Jul;82(1):227-37. doi: 10.1111/bcp.12946. Epub 2016 May 10. Br J Clin Pharmacol. 2016. PMID: 27334415 Free PMC article. Clinical Trial.
-
Autoantibodies to vimentin cause accelerated rejection of cardiac allografts.Am J Pathol. 2007 Apr;170(4):1415-27. doi: 10.2353/ajpath.2007.060728. Am J Pathol. 2007. PMID: 17392180 Free PMC article.
-
Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients.Clin Transplant. 2018 Dec;32(12):e13436. doi: 10.1111/ctr.13436. Epub 2018 Nov 18. Clin Transplant. 2018. PMID: 30372560 Free PMC article.
-
Review and Evaluation of mHealth Apps in Solid Organ Transplantation: Past, Present, and Future.Transplant Direct. 2022 Feb 21;8(3):e1298. doi: 10.1097/TXD.0000000000001298. eCollection 2022 Mar. Transplant Direct. 2022. PMID: 35368987 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
